Interstitial lung disease (ILD) progression in patients with systemic sclerosis–associated ILD (SSc-ILD) did not predict subsequent progression at the next annual follow-up, with only 20% showing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback